The subscription period for Nexam Chemical’s rights issue of shares commences today

Nexam Chemical has launched a rights issue running 26 January–9 February 2026 of up to 21,577,544 new shares at SEK 2.40 per share, providing gross proceeds of approximately SEK 51.8m and estimated issue costs of ~SEK 6.6m (including ~SEK 3.0m in underwriting compensation). About 22.1% of the issue is covered by subscription undertakings (including CEO, CFO and all board members) and c.77.9% by underwriting commitments (≈SEK 20.0m bottom and ≈SEK 20.4m top), with proceeds earmarked to accelerate commercial expansion in the Recycling business and strengthen liquidity. Key dates include trading in subscription rights 26 Jan–4 Feb, announcement of outcome on 11 Feb and expected registration in week 9, 2026.

Analysis

Market Structure: The SEK 51.8m rights issue (SEK 2.40/share, ~21.6m new shares) is immediate dilution pressure for existing holders and creates a short-term seller overhang into early Feb; parties who benefit are existing insiders who underwrite/top-subscribe (management, Mellgren, Andersson), and cash-constrained competitors who face a stronger Nexam recycling commercial rollout. Pricing power for Nexam in specialty plastics may improve if capital is efficiently deployed, but absent clear 12–24 month revenue contracts the raise mainly restores financial flexibility, not market share overnight.

Risk Assessment: Short-term (days–weeks) risks are share-price weakness, underwriter non-performance (underwriting not secured by guarantees) and FDI screening delays that can restrict institutional buyers; assign moderate probability (~10–20%) to underwriter shortfalls given 77.9% coverage and lack of bank guarantees. Medium-term (3–12 months) risks include commercialization execution, margin dilution from scaling, and covenant/cash runway risk if net proceeds (~SEK 45.2m after costs) are consumed faster than projected; tail risk includes further capital raises or a failed commercial pivot (low-probability, high-impact).

Trade Implications: Near-term tactical plays: trade TR (subscription rights) 26 Jan–4 Feb: buy TR if implied discount to theoretical ex-rights value ≥10% and sell into subscription close; consider a small directional short of stock from listing today through expected outcome 11 Feb (size 1–2% NAV, stop-loss 10%). Post-issue, if company reports clear recycling commercial orders within 6–12 months, convert to a measured long (1–3% NAV) hedged with 6–9 month puts 15–20% OTM.

Contrarian Angles: Consensus will focus on dilution; what’s missed is insiders’ top-underwriting (signals conviction) and that SEK ~45m net proceeds can materially de-risk near-term cash runway for a small First North cap — if management secures 1–2 commercial contracts in next 3–6 months upside can be >30% from depressed levels. Conversely, if FDI screening scuppers material non-EU buyers or underwriters walk, downside could be >40%; therefore size positions asymmetrically and target event-driven entry points.

Key Decisions for Investors

• If an existing shareholder, exercise pro rata rights at SEK 2.40 to avoid dilution unless you plan to reduce exposure; threshold: exercise if you expect >12-month hold and >30% upside from successful Recycling commercialisation, otherwise sell rights on market (26 Jan–4 Feb).
• Tactical short (Nexam Chemical, First North): establish a small short position equal to 1–2% of portfolio NAV from now until expected outcome announcement (cover by 18 Feb) with a hard stop-loss of 10% to capture predictable dilution/overhang risk.
• Trade subscription rights (TR): buy TRs between 26 Jan–4 Feb if they trade ≥10% below theoretical ex-rights value and flip into subscription window or immediately prior to close; target holding period ≤14 days, take-profit 8–15%.
• Post-rights conditional long: commit to a phased long of 1–3% NAV only after (a) rights registered (week 9) and (b) company announces concrete Recycling commercial contracts within 6 months; hedge initial tranche with 6–9 month puts 15–20% OTM.
• Reduce exposure to non-EU investor pools in small-cap Swedish specialty chemical names by 1–2% ahead of potential FDI screening outcomes over next 60 days; avoid initiating large buys from US/Asian accounts due to offering distribution restrictions.